Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Nursing December 2008 Susan Simmons Holcomb	Caring for a patient with chronic hepatitis C Teach your patient about improved treatments that can help him deal with this potentially deadly infection.
American Family Physician March 15, 2004	Management of Hepatitis C: Evaluating Suitability for Drug Therapy Chronic hepatitis C virus infection is a common and serious disease. Although an estimated 2.7 million persons in the United States have this disease, most have not yet been diagnosed.
American Family Physician August 15, 2005 Ward & Kugelmas	Using Pegylated Interferon and Ribavirin to Treat Patients with Chronic Hepatitis C New treatment regimens and advances in the management of side effects and toxicities have expanded the pool of patients who can be treated with pegylated interferon and ribavirin.
Nurse Practitioner December 2009 Gujral & Collantes	Understanding Viral Hepatitis: A guide for primary care Recent advancements in the field of genomics and proteomics technology have given researchers and clinicians more insight on disease pathogenesis and helped create more tailored approaches to the treatment of these conditions.
American Family Physician February 15, 2003	Antiviral Drugs in the Immunocompetent Host: Part I. Treatment of Hepatitis, Cytomegalovirus, and Herpes Infections
The Motley Fool October 31, 2007 Brian Lawler	The Next Hepatitis C Blockbuster? Never before have there been so many new drugs in development to treat Hepatitis C. Which companies have the compounds most likely to win this race? Investors, take note.
The Motley Fool October 30, 2006 Brian Lawler	Vertex's Healthy Trial Results Shares of the pharmaceutical company were up on the release of positive clinical trial data.
Nurse Practitioner February 2012 Jennifer M. Belavic	Annual drug update 2011 in review Many new medications were approved throughout 2011. This article will cover a variety of drugs that will be useful in nurse practitioner practice
American Family Physician January 15, 2006 Ann M. Khalsa	Preventive Counseling, Screening, and Therapy for the Patient with Newly Diagnosed HIV Infection The epidemic of HIV continues, and the infection is converting into a treatable chronic disease; therefore, it is increasingly important for family physicians to be current with and comfortable in providing basic care to patients infected with HIV.
Nursing March 2012 Daniel A. Hussar	New Drugs 2012: part I In this article, you'll learn about 11 recently approved drugs.
The Motley Fool April 19, 2005 Charly Travers	A Rising Star in Biotech Idenix is following a proven path to success: novel drug development. This is one biotech to keep on your watch list for the next year.
American Family Physician October 1, 2005 Francine Rainone	Milk Thistle Milk thistle has been used as a cytoprotectant for the treatment of liver disease, for the treatment and prevention of cancer, and as a supportive treatment of Amanita phalloides poisoning. Clinical studies are largely heterogeneous and contradictory.
American Family Physician November 1, 2001 Thomas R. Riley	Preventive Strategies in Chronic Liver Disease Chronic liver disease is the 10th leading cause of death in the United States. Preventive care can significantly reduce the progression of liver disease. Part I: Alcohol, Vaccines, Toxic Medications and Supplements, Diet and Exercise...
The Motley Fool December 14, 2006 Brian Lawler	Vertex: Coming Together Nicely If telaprevir continues to show anything like the 80%-90% rate of undetectable hepatitis C virus at end of its trials, Vertex shareholders won't be dealing with too many more down days.
American Family Physician March 15, 2004	Hepatitis C What is hepatitis C? How is it spread?
The Motley Fool August 10, 2007 Brian Lawler	ViroPharma Whacked by Data Shares of ViroPharma fall after safety issues come to light with one of its drugs. A phase 2 study of their hepatitis C antiviral medication has been halted, with only a slim chance of starting up again.
Nursing May 2009 Davenport & Myers	How to Protect Yourself After Body Fluid Exposure Here's how you can minimize the risk of disease transmission if you or a coworker is accidentally exposed to blood or another potentially infectious body fluid.
The Motley Fool November 6, 2007 Brian Lawler	No Surprise That Vertex Has Competition Did shares of Vertex Pharmaceuticals slump on competition concerns?
The Motley Fool April 25, 2008 Brian Lawler	Vertex Silences the Critics New clinical study data bodes well for Vertex Pharmaceuticals' lead drug.
The Motley Fool September 11, 2007 Brian Lawler	Score One for Pharmasset Shares of Pharmasset were up after the company announced impressive results for its Hepatitis C virus drug candidate R7128. Investors should continue to watch closely.
Chemistry World August 20, 2009 Sarah Houlton	Testing times: predicting hep C response A finding by David Goldstein and his group at Duke University in the US may make it possible to predict which patients are likely to benefit from the drugs, and which will probably suffer the nasty side-effects without much chance of success.
Nursing June 2011 Daniel A. Hussar	New Drugs 2011: Part 2 In this article, you'll learn about seven recently approved drugs, including: fingolimod hydrochloride, an oral drug indicated to treat patients with relapsing forms of multiple sclerosis.
Nursing February 2009 Daniel A. Hussar	New Drugs 09: Part 1 Learn about 10 new drugs, including nebivolol HCl, the newest beta-adrenergic blocking agent for hypertension.
Nursing June 2010 Daniel A. Hussar	New drugs 2010, part 2 In this article, you'll learn about 14 recently marketed new drugs.
The Motley Fool September 27, 2007 Brian Lawler	ViroPharma's Good Bad News The prospects for ViroPharma's HCV-796 darkened significantly after the company reported troubling clinical results, however, there's still hope for the compound. Investors, take note.
American Family Physician June 15, 2001 Laurie Krambeer	Methadone Therapy for Opioid Dependence Methadone maintenance therapy is the most widely known and well-researched treatment for opioid dependency. Goals of therapy are to prevent abstinence syndrome, reduce narcotic cravings and block the euphoric effects of illicit opioid use...
Chemistry World April 21, 2010 Sarah Houlton	Fresh hep C hope A new kind of compound to treat hepatitis C is showing promise in early clinical trials.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	Hepatitis C: Another Protease Revolution The launch of a new class of protease inhibitors is set to transform HCV treatment over the next decade, with kinder, gentler oral antiviral cocktails that will increase success rates from 50 percent to 75 percent.
The Motley Fool July 25, 2007 Brian Lawler	Vertex Is on Its Way Vertex Pharmaceuticals is still years away from any regulatory approval on telaprevir in the U.S., but highlights promising results so far in its quarterly report.
American Family Physician September 1, 2006 Heidelbaugh & Bruderly	Cirrhosis and Chronic Liver Failure: Part I. Diagnosis and Evaluation Part I of a two-part on how to diagnose and determine treatment for cirrhosis and chronic liver failure.
The Motley Fool October 19, 2007 Brian Lawler	Schering's Gain Is Only a Mild Headache for Vertex Schering-Plough's strong phase 2 clinical results of its hepatitis C virus drug candidate send shares of competitor Vertex down.
The Motley Fool January 8, 2008 Brian Lawler	InterMune Goes Step by Step The company updates investors on the progress of its lead drug for hepatitis C.
The Motley Fool April 3, 2008 Brian Lawler	Will InterMune's Hepatitis C Drug Compete? InterMune announces positive data for its hepatitis C treatment drug.
Chemistry World December 9, 2009 Sarah Houlton	New hep C breakthrough A drug being developed by Denmark's Santaris Pharma could provide a breakthrough in the treatment of hepatitis C, and positive results in a study on chimpanzees point to its potential to avoid drug resistance.
The Motley Fool November 8, 2007 Brian Lawler	Idenix Reels Itself In The small-cap drug developer cuts expenditures in the third quarter when sales of their hepatitis treatment don't materialize as quickly as hoped. Investors, take note.
The Motley Fool April 29, 2008 Brian Lawler	So Pharmasset, So Good Early data hints at a promising hepatitis C treatment.
The Motley Fool October 26, 2007 Brian Lawler	Another Prospect for Flamel The drug developer's good week continues with favorable news about a treatment for hepatitis C. Investors, take note.
Salon.com August 22, 2000 David Tuller	Battling the pharmaceutical Microsoft Hepatitis C activists are angry about Schering-Plough's decision to "bundle" two drugs, one of which is a potentially life-saving pill not available anywhere else.
American Family Physician November 1, 2006 Lurie et al.	Seasonal Affective Disorder Patients with seasonal affective disorder have episodes of major depression that tend to recur during specific times of the year, usually in winter. Like major depression, seasonal affective disorder probably is underdiagnosed in primary care settings.
Managed Care April 2004 Martin Sipkoff	Plans Go Directly to Patients, Describing Treatment Options HMOs are developing programs that encourage patients to question their physicians about their treatment options. Doctors are wary.
The Motley Fool June 15, 2007 Brian Lawler	Idenix Gets Knocked Shares of Idenix drop slightly after the drug developer released clinical trial results this week.
American Family Physician May 15, 2001 Thomas J. McGinnis	Significant FDA Approvals in 2000 In 2000, the medical product review staffs of the U.S. Food and Drug Administration approved 160 new drugs, biologic products and medical devices for use in the United States. Many of these approvals advance the prevention, diagnosis and treatment of serious and life-threatening diseases...
American Family Physician July 15, 2001 Marc Tunzi	Can the Patient Decide? Evaluating Patient Capacity in Practice
Pharmaceutical Executive September 1, 2013 Stan Bernard	The Drug Combination Competition Companies are leveraging combinations of drugs and other products to gain competitive advantage and market share.
Chemistry World February 19, 2015 Andrew Turley	Hepatitis C drug patent challenged in Europe A French healthcare campaign group has launched a legal challenge to the patent covering Sovaldi (sofosbuvir), the blockbuster hepatitis C virus drug marketed by Gilead.
Salon.com June 1, 2000 Tabitha M. Powledge	Gene therapy R.I.P.? When the country's biggest gene therapy institute was ordered to stop testing on humans last week, the action marked the end of an era fraught with dubious claims to success and a mess of unreported adverse effects.
Managed Care April 2005 Martin Sipkoff	Insurers Give Substance Abuse New Identity: It's a Disease After years of short shrift from payers and insurers, substance abuse services get renewed interest. Health Plans in particular are re-evaluating their approach.
The Motley Fool December 28, 2007 Brian Lawler	Cubist's Cheap Call Option As a Christmas Eve present to itself, Cubist Pharmaceuticals follows through on its October option to purchase Illumigen.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	The Next Wave: Pharm Exec's 2011 Pipeline Report 42 of the best new drugs in development or parked at the FDA
The Motley Fool April 1, 2008 Brian Lawler	Vertex Proves It ... Almost Vertex announces exciting clinical trial data that could get its anti-hepatitis C virus compound onto the market years earlier.